Calcium salts, such as calcium carbonate and calcium acetate, are the princ
ipal compounds used as phosphate binders in patients with chronic renal fai
lure. The dose required is three to six times the normal requirement for ca
lcium. Use of these large doses of calcium salts in the diet can result in
hypercalcemia. Other compounds have been investigated as phosphate binders
with varying degrees of success. Synthetic ferrihydrite (5Fe(2)O(3). 9H(2)O
) has a high adsorptive capacity for phosphate and may be an effective phos
phate binder. The phosphate-binding capacity of ferrihydrite was compared w
ith that of calcium acetate in 250-g male Sprague Dawley rats. After an ove
rnight fast, rats (n = 5 per group) were gavaged with an American Institute
of Nutrition (AIN) 76 formula containing one third the daily phosphorus in
take labeled with phosphorus-32 (P-32). Either two levels of calcium acetat
e, representing three (1/2 X) or six (1 X) times the usual calcium intake f
or one third of the day, or equivalent amounts of ferrihydrite were added t
o the diet. An additional group received two times (2 X) the larger dose, a
nd a sixth control group received no binder in the diet. Phosphorus absorpt
ion curves were determined from P-32 appearance in the serum. The 1/2 X dos
e of ferrihydrite reduced P-32 by approximately one half, and the 2 X dose
nearly completely suppressed P-32 absorption, similar to the 1 X dose of ca
lcium acetate. The advantage of using a ferrihydrite binder would be to avo
id the hypercalcemia resulting from the use of high-dose calcium salts. An
added advantage may result from the small amounts of iron absorbed in these
chronically iron-deficient patients. (C) 1999 by the National Kidney Found
ation, Inc.